Konference: 2008 33st Congress ESMO - účast ČR
Kategorie: Psychologie v onkologii
Číslo abstraktu: 856P
Methods: Patients with MCRC (ECOG PS 0–1) who had received first-line treatment with either XELOX (capecitabine 1000 mg/m2 bid for 14 days + oxaliplatin 130 mg/m2 i.v. on day 1 every 3 weeks) or FOLFOX4 were eligible. Each patient completed the Life Quality Questionnaire within 3 weeks of completion of chemotherapy. This Life Quality Questionnaire was created by collaboration between oncologists and the Institute of Psychology in order to assess MCRC patients. The Life Quality Questionnaire included several functional scales including physical, emotional, social,ability to perform everyday tasks and leisure-time activities. Respondents were also asked, given their experiences with chemotherapy, if they would prefer oral chemotherapy or continuous intravenous infusional chemotherapy assuming that the efficacy and toxicity of both chemotherapy schedules were similar.
Results: A total of 80 patients were involved; 38 had received XELOXand 42 had received FOLFOX4. In the FOLFOX4 group, 35 (83%) patients stated that they would mostly prefer oral therapy. According to the Life Quality Questionnaire, 26 (60%) patients who had received FOLFOX4 selected ‘‘neither contented nor discontented’’, ‘‘rather discontented’’ and/or ‘‘discontented’’ in their responses to individual categories. In the XELOXgroup, 35 (92%) patients stated that they would prefer oral therapy. According to the Life Quality Questionnaire, 34 (90%) of XELOX patients selected ‘‘rather contented’’,‘‘contented’’ and/or ‘‘very contented’’ as their response to individual categories. Only 4 (10%) patients in the XELOX group selected neutral or negative responses.
Conclusions: Most patients prefer oral chemotherapy. Our results further suggest that the quality of life of most patients treated with an oral fluoropyrimidine-based chemotherapy regimen is good and better than that of patients treated with a regimen based on continuous intravenous infusional 5-FU/FA.
Datum přednesení příspěvku: 12. 9. 2008